Ph 3 trial of SYK inhibitor, entospletinib, for the treatment of newly diagnosed patients with NPM1-mutated AML to be discontinued
“Focusing on lanraplenib and KB-0742 will allow us to direct our resources to the highest value programs and deliver on our mission of bringing cancer drugs to the patients with the greatest need,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio. “This is the right decision at the right time, and it makes us a stronger company as a result. I want to express my gratitude to the clinicians and the patients who participated in our entospletinib trial, as well as our employees, for their contributions to advancing potential new therapies to treat AML.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.